Cutaneous melanoma and the immunotherapy revolution (Review)
In a relatively short period of time, treatment strategies for metastatic melanoma have radically changed leading to an unprecedented improvement in patient survival. In this period, immunotherapy options have evolved from cytokine‑based approaches to antibody‑mediated inhibition of immune checkpoin...
Gespeichert in:
| Veröffentlicht in: | International journal of oncology 2020-09, Vol.57 (3), p.609-618 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 618 |
|---|---|
| container_issue | 3 |
| container_start_page | 609 |
| container_title | International journal of oncology |
| container_volume | 57 |
| creator | Leonardi, Giulia C Candido, Saverio Falzone, Luca Spandidos, Demetrios A Libra, Massimo |
| description | In a relatively short period of time, treatment strategies for metastatic melanoma have radically changed leading to an unprecedented improvement in patient survival. In this period, immunotherapy options have evolved from cytokine‑based approaches to antibody‑mediated inhibition of immune checkpoints, cancer vaccines and pharmacological modulation of the melanoma microenvironment. Combination of immunotherapy strategies and the association of immune checkpoint inhibitors (ICIs) with BRAF V600 targeted therapy show encouraging results. The future of drug development in this field is promising. The comprehension of primary and acquired resistance mechanisms to ICIs and the dissection of melanoma immunobiology will be instrumental for the development of new treatment strategies and to improve clinical trial design. Moreover, biomarker discovery will help patient stratification and management during immunotherapy treatment. In this review, we summarize landmark clinical trials of immune checkpoint inhibitors in advanced melanoma and discuss the rational for immunotherapy combinations. Immunotherapy approaches at early stage of clinical development and recent advances in melanoma immunotherapy biomarker development are also discussed. |
| doi_str_mv | 10.3892/ijo.2020.5088 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7384846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A633545574</galeid><sourcerecordid>A633545574</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-7c780017fc8c8edf428b88af557e3603c25421c6c8c1c919dd584b01dfb1ce3f3</originalsourceid><addsrcrecordid>eNptkd9LHDEQx4NUqrV99LUsFEp92DM_dxOQghytFoSCtM8hl514OXaTa7J74n9vDq_qgczDDJnPfJnMF6FTgmdMKnruV3FGMcUzgaU8QMekVaSmnLJ3pcZE1Q1n6gh9yHmFMRUCk_foiFEhqWrYMbqYT6MJEKdcDdCbEAdTmdBV4xIqPwxTiKVKZv1QJdjEfhp9DNW3W9h4uD_7iA6d6TN82uUT9Pfnjz_z6_rm99Wv-eVNbUWrxrq1rcSYtM5KK6FznMqFlMYJ0QJrMLNUcEpsU9rEKqK6Tki-wKRzC2KBOXaCvj_prqfFAJ2FMCbT63Xyg0kPOhqv9zvBL_Vd3OiWSS55UwS-7ARS_DdBHvUqTimUnTXlDCsupGpfqDvTg_bBxSJmB5-tvmwYE7wszAs1e4Mq0cHgbQzgfHnfG_j6amAJph-XeXfKvA_WT6BNMecE7vmHBOut2bqYrbdm663Zhf_8-izP9H932SP8KKPU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430945897</pqid></control><display><type>article</type><title>Cutaneous melanoma and the immunotherapy revolution (Review)</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Leonardi, Giulia C ; Candido, Saverio ; Falzone, Luca ; Spandidos, Demetrios A ; Libra, Massimo</creator><creatorcontrib>Leonardi, Giulia C ; Candido, Saverio ; Falzone, Luca ; Spandidos, Demetrios A ; Libra, Massimo</creatorcontrib><description>In a relatively short period of time, treatment strategies for metastatic melanoma have radically changed leading to an unprecedented improvement in patient survival. In this period, immunotherapy options have evolved from cytokine‑based approaches to antibody‑mediated inhibition of immune checkpoints, cancer vaccines and pharmacological modulation of the melanoma microenvironment. Combination of immunotherapy strategies and the association of immune checkpoint inhibitors (ICIs) with BRAF V600 targeted therapy show encouraging results. The future of drug development in this field is promising. The comprehension of primary and acquired resistance mechanisms to ICIs and the dissection of melanoma immunobiology will be instrumental for the development of new treatment strategies and to improve clinical trial design. Moreover, biomarker discovery will help patient stratification and management during immunotherapy treatment. In this review, we summarize landmark clinical trials of immune checkpoint inhibitors in advanced melanoma and discuss the rational for immunotherapy combinations. Immunotherapy approaches at early stage of clinical development and recent advances in melanoma immunotherapy biomarker development are also discussed.</description><identifier>ISSN: 1019-6439</identifier><identifier>EISSN: 1791-2423</identifier><identifier>DOI: 10.3892/ijo.2020.5088</identifier><identifier>PMID: 32582963</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Antibodies ; Antigens ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Biological Products - pharmacology ; Biomarkers ; Biomarkers, Tumor - immunology ; Cancer metastasis ; Cancer therapies ; Cancer vaccines ; Cancer Vaccines - immunology ; Cancer Vaccines - pharmacology ; Clinical trials ; CTLA-4 Antigen - antagonists & inhibitors ; Cytokines ; Drug development ; Drug therapy ; FDA approval ; Herpesvirus 1, Human ; Humans ; Immune Checkpoint Inhibitors - pharmacology ; Immunity, Innate - drug effects ; Immunotherapy ; Immunotherapy - methods ; Ipilimumab ; Medical prognosis ; Melanoma ; Melanoma - therapy ; Melanoma, Cutaneous Malignant ; Metastasis ; Microbiota - immunology ; Molecular Targeted Therapy ; Nivolumab ; Patients ; Pembrolizumab ; Programmed Cell Death 1 Receptor - analysis ; Skin cancer ; Skin Neoplasms - therapy ; Talimogene laherparepvec ; Tumor Microenvironment - immunology ; Tumors ; Vaccines</subject><ispartof>International journal of oncology, 2020-09, Vol.57 (3), p.609-618</ispartof><rights>COPYRIGHT 2020 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Leonardi et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-7c780017fc8c8edf428b88af557e3603c25421c6c8c1c919dd584b01dfb1ce3f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32582963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leonardi, Giulia C</creatorcontrib><creatorcontrib>Candido, Saverio</creatorcontrib><creatorcontrib>Falzone, Luca</creatorcontrib><creatorcontrib>Spandidos, Demetrios A</creatorcontrib><creatorcontrib>Libra, Massimo</creatorcontrib><title>Cutaneous melanoma and the immunotherapy revolution (Review)</title><title>International journal of oncology</title><addtitle>Int J Oncol</addtitle><description>In a relatively short period of time, treatment strategies for metastatic melanoma have radically changed leading to an unprecedented improvement in patient survival. In this period, immunotherapy options have evolved from cytokine‑based approaches to antibody‑mediated inhibition of immune checkpoints, cancer vaccines and pharmacological modulation of the melanoma microenvironment. Combination of immunotherapy strategies and the association of immune checkpoint inhibitors (ICIs) with BRAF V600 targeted therapy show encouraging results. The future of drug development in this field is promising. The comprehension of primary and acquired resistance mechanisms to ICIs and the dissection of melanoma immunobiology will be instrumental for the development of new treatment strategies and to improve clinical trial design. Moreover, biomarker discovery will help patient stratification and management during immunotherapy treatment. In this review, we summarize landmark clinical trials of immune checkpoint inhibitors in advanced melanoma and discuss the rational for immunotherapy combinations. Immunotherapy approaches at early stage of clinical development and recent advances in melanoma immunotherapy biomarker development are also discussed.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Biological Products - pharmacology</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Cancer metastasis</subject><subject>Cancer therapies</subject><subject>Cancer vaccines</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - pharmacology</subject><subject>Clinical trials</subject><subject>CTLA-4 Antigen - antagonists & inhibitors</subject><subject>Cytokines</subject><subject>Drug development</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Herpesvirus 1, Human</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - pharmacology</subject><subject>Immunity, Innate - drug effects</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Ipilimumab</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Melanoma - therapy</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Metastasis</subject><subject>Microbiota - immunology</subject><subject>Molecular Targeted Therapy</subject><subject>Nivolumab</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Programmed Cell Death 1 Receptor - analysis</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - therapy</subject><subject>Talimogene laherparepvec</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>1019-6439</issn><issn>1791-2423</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkd9LHDEQx4NUqrV99LUsFEp92DM_dxOQghytFoSCtM8hl514OXaTa7J74n9vDq_qgczDDJnPfJnMF6FTgmdMKnruV3FGMcUzgaU8QMekVaSmnLJ3pcZE1Q1n6gh9yHmFMRUCk_foiFEhqWrYMbqYT6MJEKdcDdCbEAdTmdBV4xIqPwxTiKVKZv1QJdjEfhp9DNW3W9h4uD_7iA6d6TN82uUT9Pfnjz_z6_rm99Wv-eVNbUWrxrq1rcSYtM5KK6FznMqFlMYJ0QJrMLNUcEpsU9rEKqK6Tki-wKRzC2KBOXaCvj_prqfFAJ2FMCbT63Xyg0kPOhqv9zvBL_Vd3OiWSS55UwS-7ARS_DdBHvUqTimUnTXlDCsupGpfqDvTg_bBxSJmB5-tvmwYE7wszAs1e4Mq0cHgbQzgfHnfG_j6amAJph-XeXfKvA_WT6BNMecE7vmHBOut2bqYrbdm663Zhf_8-izP9H932SP8KKPU</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Leonardi, Giulia C</creator><creator>Candido, Saverio</creator><creator>Falzone, Luca</creator><creator>Spandidos, Demetrios A</creator><creator>Libra, Massimo</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20200901</creationdate><title>Cutaneous melanoma and the immunotherapy revolution (Review)</title><author>Leonardi, Giulia C ; Candido, Saverio ; Falzone, Luca ; Spandidos, Demetrios A ; Libra, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-7c780017fc8c8edf428b88af557e3603c25421c6c8c1c919dd584b01dfb1ce3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Biological Products - pharmacology</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Cancer metastasis</topic><topic>Cancer therapies</topic><topic>Cancer vaccines</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - pharmacology</topic><topic>Clinical trials</topic><topic>CTLA-4 Antigen - antagonists & inhibitors</topic><topic>Cytokines</topic><topic>Drug development</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Herpesvirus 1, Human</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - pharmacology</topic><topic>Immunity, Innate - drug effects</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Ipilimumab</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Melanoma - therapy</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Metastasis</topic><topic>Microbiota - immunology</topic><topic>Molecular Targeted Therapy</topic><topic>Nivolumab</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Programmed Cell Death 1 Receptor - analysis</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - therapy</topic><topic>Talimogene laherparepvec</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Leonardi, Giulia C</creatorcontrib><creatorcontrib>Candido, Saverio</creatorcontrib><creatorcontrib>Falzone, Luca</creatorcontrib><creatorcontrib>Spandidos, Demetrios A</creatorcontrib><creatorcontrib>Libra, Massimo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leonardi, Giulia C</au><au>Candido, Saverio</au><au>Falzone, Luca</au><au>Spandidos, Demetrios A</au><au>Libra, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cutaneous melanoma and the immunotherapy revolution (Review)</atitle><jtitle>International journal of oncology</jtitle><addtitle>Int J Oncol</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>57</volume><issue>3</issue><spage>609</spage><epage>618</epage><pages>609-618</pages><issn>1019-6439</issn><eissn>1791-2423</eissn><abstract>In a relatively short period of time, treatment strategies for metastatic melanoma have radically changed leading to an unprecedented improvement in patient survival. In this period, immunotherapy options have evolved from cytokine‑based approaches to antibody‑mediated inhibition of immune checkpoints, cancer vaccines and pharmacological modulation of the melanoma microenvironment. Combination of immunotherapy strategies and the association of immune checkpoint inhibitors (ICIs) with BRAF V600 targeted therapy show encouraging results. The future of drug development in this field is promising. The comprehension of primary and acquired resistance mechanisms to ICIs and the dissection of melanoma immunobiology will be instrumental for the development of new treatment strategies and to improve clinical trial design. Moreover, biomarker discovery will help patient stratification and management during immunotherapy treatment. In this review, we summarize landmark clinical trials of immune checkpoint inhibitors in advanced melanoma and discuss the rational for immunotherapy combinations. Immunotherapy approaches at early stage of clinical development and recent advances in melanoma immunotherapy biomarker development are also discussed.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>32582963</pmid><doi>10.3892/ijo.2020.5088</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1019-6439 |
| ispartof | International journal of oncology, 2020-09, Vol.57 (3), p.609-618 |
| issn | 1019-6439 1791-2423 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7384846 |
| source | Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies Antigens Antineoplastic Combined Chemotherapy Protocols - pharmacology Biological Products - pharmacology Biomarkers Biomarkers, Tumor - immunology Cancer metastasis Cancer therapies Cancer vaccines Cancer Vaccines - immunology Cancer Vaccines - pharmacology Clinical trials CTLA-4 Antigen - antagonists & inhibitors Cytokines Drug development Drug therapy FDA approval Herpesvirus 1, Human Humans Immune Checkpoint Inhibitors - pharmacology Immunity, Innate - drug effects Immunotherapy Immunotherapy - methods Ipilimumab Medical prognosis Melanoma Melanoma - therapy Melanoma, Cutaneous Malignant Metastasis Microbiota - immunology Molecular Targeted Therapy Nivolumab Patients Pembrolizumab Programmed Cell Death 1 Receptor - analysis Skin cancer Skin Neoplasms - therapy Talimogene laherparepvec Tumor Microenvironment - immunology Tumors Vaccines |
| title | Cutaneous melanoma and the immunotherapy revolution (Review) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A18%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cutaneous%20melanoma%20and%20the%20immunotherapy%20revolution%20(Review)&rft.jtitle=International%20journal%20of%20oncology&rft.au=Leonardi,%20Giulia%20C&rft.date=2020-09-01&rft.volume=57&rft.issue=3&rft.spage=609&rft.epage=618&rft.pages=609-618&rft.issn=1019-6439&rft.eissn=1791-2423&rft_id=info:doi/10.3892/ijo.2020.5088&rft_dat=%3Cgale_pubme%3EA633545574%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2430945897&rft_id=info:pmid/32582963&rft_galeid=A633545574&rfr_iscdi=true |